Summary & Overview
HCPCS J0577: Buprenorphine Extended-Release Injection, Short Course
HCPCS Level II code J0577 denotes administration of buprenorphine extended-release (Brixadi) for treatment courses of seven days or fewer. This injectable formulation is used in the management of opioid use disorder and is notable for its extended-release delivery in a short-course dosing window. Nationally, use of extended-release buprenorphine formulations intersects clinical pathways for medication-assisted treatment and payer coverage policies that shape access and site-of-service decisions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage considerations, typical sites of service, and operational implications for outpatient administration. The publication summarizes benchmark elements related to utilization and reimbursement patterns where available, highlights relevant policy updates affecting injectable buprenorphine products, and provides clinical context on how short-course extended-release dosing fits into treatment strategies.
This summary is intended for clinicians, billing professionals, and policy analysts seeking a national perspective on coding and administrative considerations for J0577. Data not available in the input will be noted where appropriate in the full publication.
Billing Code Overview
HCPCS Level II code J0577 represents an injection of buprenorphine extended-release (Brixadi) for a treatment course of less than or equal to 7 days of therapy. This code covers the administration of the extended-release buprenorphine formulation indicated for opioid use disorder when the dosing regimen corresponds to a short-duration treatment period.
Service Type: Medication administration (injectable extended-release buprenorphine)
Typical Site of Service: Outpatient clinic, ambulatory infusion center, or other outpatient facility where injectable medications are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with moderate-to-severe opioid use disorder presents to an outpatient medication-assisted treatment (MAT) clinic for initiation of long-acting buprenorphine therapy. The clinician confirms recent opioid withdrawal or a transition plan from transmucosal buprenorphine, reviews informed consent, and documents clinical stability, counseling, and monitoring plans. The patient receives a single subcutaneous injection of extended-release buprenorphine (J0577, less than or equal to 7 days of therapy) administered by a trained nurse in a treatment area equipped for observation. Post-injection observation for adverse reactions and brief counseling are provided. Follow-up is scheduled within 7 days to assess response, injection site, withdrawal control, and ongoing psychosocial supports.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Not typically appended; default when no other modifier applies |
23 | Unusual anesthesia | If unusual anesthesia unrelated to the injection is required |